Bedford Laboratories Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
BEDFORD, Ohio, Jan. 3 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., announced the acquisition of CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. CAFCIT(R) (caffeine citrate) is indicated for the short term treatment of apnea in premature infants between 28 and <33 weeks gestational age.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
"The acquisition of CAFCIT(R) demonstrates our continued commitment to build the most comprehensive and cost effective line of injectable products in the pharmaceutical industry. We are proud to offer a branded product at a generic price," said David Gaugh, Vice President and General Manager of Bedford Laboratories.
Bedford Laboratories will supply latex free CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution as a sterile liquid in the following presentations:
Prescribing information is available upon request from the Bedford Laboratories' professional services department, (800) 521-5169, or from the company's web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the US and international markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business, segment Prescription Medicines, on research and development.
For more information, please visit. http://us.boehringer-ingelheim.com .
CONTACT: Jason Kurtz of Bedford Laboratories, +1-800-562-4797, ext 3668,
Jason.Kurtz@boehringer-ingelheim.com
Web site: http://www.bedfordlabs.com/
http://us.boehringer-ingelheim.com/